A Study of PRT3645 in Participants With Select Advanced or Metastatic Solid Tumors

Summary

This is a Phase 1 dose-escalation study of PRT3645, a Cyclin-dependent Kinase 4/6 (CDK4/6) inhibitor, in patients with advanced or metastatic solid tumors. The purpose of this study is to investigate the safety, tolerability, dose limiting toxicity, and to determine maximally tolerated dose and recommended phase 2 dose to be used in subsequent development of PRT3645.

Timeline

Start

2022-12-27

Primary completion

2024-06-26

Completion

2024-06-26

Drugs

Indications